Effects of anti-inflammatory agents on cardiovascular outcomes: A systematic review and meta-analysis of randomised controlled trials.

BACKGROUND

Inflammation is causally implicated in the development and progression of atherosclerotic cardiovascular disease, but clinical trials of anti-inflammatory therapies have yielded inconsistent effects on cardiovascular outcomes.

METHODS

We conducted a systematic review and meta-analysis to evaluate the cardiovascular efficacy and safety of a broad range of anti-inflammatory agents. Medline, Embase and Cochrane databases were searched from inception to 08 October 2024 for randomised controlled trials evaluating the effect of anti-inflammatory therapies on a primary cardiovascular outcome with at least 100 patient-years follow-up per treatment arm. Trial level meta-analysis was performed using a random effects model. The primary outcome was major adverse cardiovascular events (MACE); other outcomes included myocardial infarction, stroke, heart failure, serious adverse events, infection, and malignancy.

RESULTS

Thirteen trials enrolling 82,208 participants were included. The effect of anti-inflammatory agents on MACE varied by drug class (P-heterogeneity=0.049), driven primarily by benefits observed with colchicine (RR 0.76; 95 % CI 0.65-0.90; moderate certainty) and canakinumab (RR 0.88; 95 % CI 0.79-0.97; moderate certainty), with no benefit observed for other agents. Among colchicine trials, heterogeneity was identified (P-heterogeneity=0.003), and subgroup analyses suggested greater benefit in coronary artery disease and/or recent myocardial infarction trials (P-heterogeneity=0.068). Safety outcomes also varied by drug class, with significant heterogeneity in serious adverse events (P-heterogeneity=0.005), largely attributable to methotrexate, and some evidence of heterogeneity for infection (P-heterogeneity=0.076) and malignancy (P-heterogeneity=0.077).

CONCLUSION

Some anti-inflammatory agents may reduce the risk of cardiovascular outcomes, but their effects appear to vary substantially across drug classes, with important differences in both efficacy and safety. These findings underscore the need for rigorous evaluation of new anti-inflammatory therapeutics to ascertain benefits and harms across different populations and therapeutic indications.